glp-1 depression New study confirms medications are safe for mental health in diabetes Glucagon-like peptide-1 medicines in neurological

Weekly injection schedules are considered optimal for the following reasons: Stable drug levels: Weekly administration helps maintain consistent therapeutic effects

For 2,567 semaglutide users who stopped treatment, 33% regained weight, 32% maintained weight loss, and 35% continued losing weight

Friedman School of Nutrition Science and Policy at Tufts University, recently served as lead chair and author of a clinical advisory titled Nutritional Priorities to Support GLP-1 Therapy for Obesity, published across four peer-reviewed journals and issued by four leading organizations in lifestyle medicine, obesity medicine, and nutritionthe American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine Association (OMA), and The Obesity Society (TOS)

The release of those numbers comes just days after a watershed federal policy change: beginning July 1, 2026, eligible Medicare Part D beneficiaries can access GLP-1 medications approved for weight loss including Wegovy, oral Wegovy, Zepbound, and Foundayo for a flat $50 monthly copay through a new program called the Medicare GLP-1 Bridge

Zepbound Side Effects and Health Risks While Zepbound has been able to help many patients with glucose management and weight loss, there are multiple concerns about negative side effects